- Truist Securities BioPharma Symposium: Panel discussion on
Wednesday, November 8 at10:45 a.m. ET inNew York . Jefferies London Healthcare Conference : Presentation onWednesday, November 15 at12:00 p.m. GMT (7:00 a.m. ET ) inLondon, England .Evercore ISI HealthCONx Conference : Fireside chat onThursday, November 30 at10:00 a.m. ET inMiami .
RayzeBio will also be participating in 1x1 investor meetings at these conferences.
About RayzeBio
RayzeBio is building a vertically integrated radiopharmaceutical therapeutics (RPT) company to treat various cancers, with its lead program in a Phase 3 clinical trial. RayzeBio has created a pipeline of multiple drug candidates in therapeutic areas with significant market opportunities. Much like antibody drug conjugates emerged as a new and transformative treatment modality in certain cancers, the company sees an opportunity for innovative radiopharmaceutical therapeutics to follow a similar path. RayzeBio believes its strategic investments in building a robust product pipeline, development capabilities, and manufacturing infrastructure position the company to be an industry-leading pioneer in the broad application of RPT for cancer.
Contact: Arvind Kush
Email: info@rayzebio.com
Source:
2023 GlobeNewswire, Inc., source